• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Trastuzumab is not a tyrosine kinase inhibitor.

作者信息

Mohan Nishant, Wu Wen Jin

机构信息

Division of Biotechnology Research and Review I, Office of Biotechnology Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20993, USA.

出版信息

Nat Rev Cardiol. 2015 Nov;12(11):669. doi: 10.1038/nrcardio.2015.135. Epub 2015 Sep 29.

DOI:10.1038/nrcardio.2015.135
PMID:26416004
Abstract
摘要

相似文献

1
Trastuzumab is not a tyrosine kinase inhibitor.曲妥珠单抗不是一种酪氨酸激酶抑制剂。
Nat Rev Cardiol. 2015 Nov;12(11):669. doi: 10.1038/nrcardio.2015.135. Epub 2015 Sep 29.
2
Mechanisms underlying trastuzumab activity are complex.曲妥珠单抗活性的潜在机制很复杂。
Nat Rev Cardiol. 2015 Nov;12(11):669. doi: 10.1038/nrcardio.2015.136. Epub 2015 Sep 29.
3
Anthracycline- and trastuzumab-induced cardiotoxicity: a retrospective study.蒽环类药物和曲妥珠单抗引起的心脏毒性：一项回顾性研究。
Med Oncol. 2016 Jul;33(7):82. doi: 10.1007/s12032-016-0797-x. Epub 2016 Jun 22.
4
Antiblastic drug-induced cardiotoxicity and cardioprotection: a compendium.抗有丝分裂药物诱导的心脏毒性与心脏保护：综述
J Cardiovasc Med (Hagerstown). 2016 May;17 Suppl 1:e1-e2. doi: 10.2459/JCM.0000000000000384.
5
Biomarkers as Predictors of Cardiac Toxicity From Targeted Cancer Therapies.生物标志物可预测靶向癌症疗法的心脏毒性。
J Card Fail. 2016 Jun;22(6):459-64. doi: 10.1016/j.cardfail.2016.03.016. Epub 2016 Mar 30.
6
The role of cardiac biomarkers as predictors of trastuzumab cardiotoxicity in patients with breast cancer.心脏生物标志物在乳腺癌患者中作为曲妥珠单抗心脏毒性预测指标的作用。
Exp Oncol. 2015 Mar;37(1):53-7.
7
[Biochemical predictors of anthracyclin and trastuzumab induced cardiotoxicity in early diagnostics of cardiomyopathy].[蒽环类药物和曲妥珠单抗诱导的心脏毒性在心肌病早期诊断中的生化预测指标]
Pol Merkur Lekarski. 2016 Jan;40(235):40-5.
8
[Cancer therapy-induced cardiotoxicity].[癌症治疗引起的心脏毒性]
Rev Med Liege. 2016 Sep;71(9):382-387.
9
Overweight in mice, induced by perinatal programming, exacerbates doxorubicin and trastuzumab cardiotoxicity.围产期编程诱导的小鼠超重会加剧阿霉素和曲妥珠单抗的心脏毒性。
Cancer Chemother Pharmacol. 2016 Apr;77(4):777-85. doi: 10.1007/s00280-016-2995-9. Epub 2016 Feb 25.
10
[Diagnostic imaging methods of cardiac dysfunction caused by cardiotoxicity of oncological therapy].[肿瘤治疗心脏毒性所致心脏功能障碍的诊断成像方法]
Pol Merkur Lekarski. 2016 Jan;40(235):36-9.

引用本文的文献

1
A Comprehensive Overview on Chemotherapy-Induced Cardiotoxicity: Insights into the Underlying Inflammatory and Oxidative Mechanisms.化疗诱导的心脏毒性综合概述：对潜在炎症和氧化机制的见解
Cardiovasc Drugs Ther. 2024 Mar 16. doi: 10.1007/s10557-024-07574-0.
2
Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers.曲妥珠单抗介导的心脏毒性：当前的认识、挑战与前沿进展
Antib Ther. 2018 Aug 31;1(1):13-17. doi: 10.1093/abt/tby003.
3
Mechanisms underlying trastuzumab activity are complex.曲妥珠单抗活性的潜在机制很复杂。

本文引用的文献

1
Cardiotoxicity of anticancer treatments.抗癌治疗的心脏毒性。
Nat Rev Cardiol. 2015 Sep;12(9):547-58. doi: 10.1038/nrcardio.2015.65. Epub 2015 May 12.
2
Trastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibition.曲妥珠单抗诱导的Csk同源激酶（CHK）募集至ErbB2受体与ErbB2-Y1248磷酸化及ErbB2降解相关，从而介导细胞生长抑制。
Cancer Biol Ther. 2014 Aug;15(8):1029-41. doi: 10.4161/cbt.29171. Epub 2014 May 16.
3
HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer.
Nat Rev Cardiol. 2015 Nov;12(11):669. doi: 10.1038/nrcardio.2015.136. Epub 2015 Sep 29.
HER2 磷酸化通过 PKB 负反馈环维持，以响应乳腺癌中的抗 HER2 赫赛汀。
PLoS Biol. 2010 Dec 21;8(12):e1000563. doi: 10.1371/journal.pbio.1000563.
4
Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.拉帕替尼：一种人表皮生长因子受体酪氨酸激酶的双重抑制剂。
Clin Ther. 2008 Aug;30(8):1426-47. doi: 10.1016/j.clinthera.2008.08.008.
5
Trastuzumab--mechanism of action and use in clinical practice.曲妥珠单抗——作用机制及临床应用
N Engl J Med. 2007 Jul 5;357(1):39-51. doi: 10.1056/NEJMra043186.
6
Epidermal growth factor receptor targeting in cancer.癌症中的表皮生长因子受体靶向治疗
Semin Oncol. 2006 Aug;33(4):369-85. doi: 10.1053/j.seminoncol.2006.04.003.
7
Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.表皮生长因子受体共表达通过特定的erbB受体相互作用和激活来调节HER2/neu过表达乳腺癌细胞对赫赛汀的敏感性。
Exp Cell Res. 2005 Apr 1;304(2):604-19. doi: 10.1016/j.yexcr.2004.12.008. Epub 2005 Jan 21.
8
The EGF receptor family as targets for cancer therapy.作为癌症治疗靶点的表皮生长因子受体家族
Oncogene. 2000 Dec 27;19(56):6550-65. doi: 10.1038/sj.onc.1204082.
9
p185HER2 signal transduction in breast cancer cells.
J Biol Chem. 1991 Aug 5;266(22):14300-5.